Liu Hai-Ting, Mu De-Zhi
Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2014 Sep;16(9):962-7.
Brain hypoxia-ischemia has been considered as critical factors in many human central nervous system diseases, including stroke and neonatal hypoxic-ischemic encephalopathy. In brain hypoxia-ischemia processes, inducible NO synthase (iNOS) is induced to produce excessive nitric oxide (NO) which leads to cascade reactions of inflammation and neuronal death, deteriorating primary brain injury. Inhibiting iNOS expression has opened new perspectives in the treatment of brain hypoxia-ischemia because iNOS inhibitor has been shown as a potent therapeutic agent. This reviews focus on recent research achievements regarding the relationship between iNOS and ischemic-hypoxic brain damage and the perspective of using iNOS inhibitors as therapeutic strategies for brain ischemic-hypoxic brain damage.
脑缺氧缺血被认为是许多人类中枢神经系统疾病的关键因素，包括中风和新生儿缺氧缺血性脑病。在脑缺氧缺血过程中，诱导型一氧化氮合酶（iNOS）被诱导产生过量的一氧化氮（NO），这会导致炎症和神经元死亡的级联反应，使原发性脑损伤恶化。抑制iNOS表达为脑缺氧缺血的治疗开辟了新的前景，因为iNOS抑制剂已被证明是一种有效的治疗药物。这篇综述聚焦于iNOS与缺血缺氧性脑损伤之间关系的最新研究成果，以及使用iNOS抑制剂作为脑缺血缺氧性脑损伤治疗策略的前景。
